Li Xiaofan, Shorter Daryl, Kosten Thomas R
LI, SHORTER, and KOSTEN: Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX SHORTER and KOSTEN: Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
J Psychiatr Pract. 2016 May;22(3):183-92. doi: 10.1097/PRA.0000000000000154.
As a result of the prescription opioid epidemic in the United States, there has been an increasing need for effective treatment interventions, both pharmacological and nonpharmacological. Buprenorphine has emerged as a critical component of the treatment of opioid use disorder, yet its adoption has not been without some concerns. This article first reviews the pharmacology, clinical use, and US legislative action related to buprenorphine, followed by a discussion of the misuse and diversion of buprenorphine in the United States as well as internationally. We then explore the impact of buprenorphine abuse as well as discussing strategies for its reduction, including changes in policy, prescription and pharmacy monitoring, and continuing medical education for guiding and improving clinical practice.
由于美国处方阿片类药物泛滥，对有效的药物和非药物治疗干预措施的需求日益增加。丁丙诺啡已成为阿片类药物使用障碍治疗的关键组成部分，但其应用并非毫无问题。本文首先回顾与丁丙诺啡相关的药理学、临床应用和美国立法行动，接着讨论丁丙诺啡在美国以及国际上的滥用和转移问题。然后，我们探讨丁丙诺啡滥用的影响，并讨论减少其滥用的策略，包括政策变化、处方和药房监测，以及指导和改进临床实践的继续医学教育。
